As of June 4, 2025, Gan & Lee Pharmaceuticals (603087.SS) reports a ROA (Return on Assets) of 5.10%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Gan & Lee Pharmaceuticals's ROA (Return on Assets)
Over recent years, Gan & Lee Pharmaceuticals's ROA (Return on Assets) has shown significant volatility. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | 5.10% |
| 2023-12-31 | 2.90% |
| 2022-12-31 | -4.14% |
| 2021-12-31 | 13.39% |
| 2020-12-31 | 12.94% |
This slight downward trend highlights how Gan & Lee Pharmaceuticals manages its efficiency in using assets to generate earnings over time.
Comparing Gan & Lee Pharmaceuticals's ROA (Return on Assets) to Peers
To better understand Gan & Lee Pharmaceuticals's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Gan & Lee Pharmaceuticals (603087.SS) | 5.10% |
| Xiamen Amoytop Biotech Co Ltd (688278.SS) | 27.13% |
| Imeik Technology Development Co Ltd (300896.SZ) | 23.47% |
| Shenzhen New Industries Biomedical Engineering Co Ltd (300832.SZ) | 19.01% |
| Anhui Anke Biotechnology Group Co Ltd (300009.SZ) | 13.77% |
| Amoy Diagnostics Co Ltd (300685.SZ) | 12.34% |
Compared to its competitors, Gan & Lee Pharmaceuticals's ROA (Return on Assets) is about average compared to peers, indicating typical asset efficiency for the industry.